Requisite Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Requisite Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-30,000	Closed	-$11K	–	62
2019 Q4	$11K	Buy	+30,000	New	+$1.72M	﹤0.01%	78
2019 Q2	–	Sell	-16,000	Closed	-$25K	–	105
2019 Q1	$25K	Buy	+16,000	New	+$797K	0.01%	138

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Requisite Capital Management's BMY Position: Q4 2025 in Review

Requisite Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 4,987 shares — an estimated $225K sold.

Requisite Capital Management first reported a position in BMY in Q1 2019 and held it in 5 quarters. The position peaked at $948K in Q3 2019. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Requisite Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Requisite Capital Management sold 4,987 Bristol-Myers Squibb shares in Q4 2025, an estimated $225K.
Requisite Capital Management first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 5 quarters.
Requisite Capital Management's Bristol-Myers Squibb position peaked at $948K in Q3 2019.
2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Requisite Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.